• Magali Lecavalier-Barsoum, Daniel Roy, Robert Doucet, Bernard Fortin, Carole Lambert, Robert Moumdjian, and Jean-Paul Bahary.
• Radiation Oncology Department, McGill University Health Center, Canada. Magali.lecavalier@mail.mcgill.ca
• Can J Neurol Sci. 2013 Mar 1; 40 (2): 182-6.

BackgroundStereotactic radiosurgery (SRS) is known to safely result in a high obliteration rate for small and medium sized arteriovenous malformations (AVM).ObjectiveTo evaluate the long-term outcome of patients treated with SRS, with special emphasis given to obliteration and toxicity rates.MethodsWe performed a review of 43 cerebral AVM patients, treated from 1998 to 2008 with a single SRS dose ranging from 21-25 Gy. Of these, 37 had a minimal follow-up of one year. Medical files were reviewed to assess patient and AVM characteristics, the SRS treatment, therapy prior to SRS, the obliteration rate and toxicities. Whenever necessary, outcome data was supplemented by telephone interviews with the patient or treating physician.ResultsAVM size was ≥3cm in diameter in 21% of patients. Five patients (11.6%) underwent surgery prior to SRS and 31 patients (72.1%) received one or more embolizations prior to SRS. Of the patients followed with angiography ≥1 year post-SRS, 89% (33/37) had a complete obliteration of the nidus, after a median time of 24.7 months post-treatment. Embolization prior to SRS was not predictive of outcome. One patient suffered a non-fatal haemorrhage between treatment and obliteration. The rate of symptomatic radiation-induced radiological changes was 8.1%.ConclusionOur study shows both obliteration and complication rates in the upper limit of those reported in the literature. SRS seems an attractive treatment option for small AVMs. Unlike other reports, the prior use of embolization did not impact negatively on obliteration rates.

22 keywords...

hide…